ID   KP-N-YS
AC   CVCL_1342
SY   KPNYS; Kyoto Pediatrics-Neuroblastoma-YS
DR   CLO; CLO_0037080
DR   ArrayExpress; E-MTAB-783
DR   BioGRID_ORCS_Cell_line; 916
DR   cancercelllines; CVCL_1342
DR   Cell_Model_Passport; SIDM00157
DR   CGH-DB; 82-1
DR   CGH-DB; 9083-4
DR   ChEMBL-Cells; CHEMBL3308266
DR   ChEMBL-Targets; CHEMBL2366065
DR   Cosmic; 946363
DR   Cosmic-CLP; 946363
DR   DepMap; ACH-002261
DR   GDSC; 946363
DR   GEO; GSM1670008
DR   IARC_TP53; 27174
DR   LINCS_LDP; LCL-1986
DR   PharmacoDB; KPNYS_789_2019
DR   PRIDE; PXD030304
DR   PubChem_Cell_line; CVCL_1342
DR   Wikidata; Q54900406
RX   CelloPub=CLPUB00582;
RX   PubMed=10363161;
RX   PubMed=11129446;
RX   PubMed=12702577;
RX   PubMed=20164919;
RX   PubMed=23268333;
RX   PubMed=27397505;
RX   PubMed=30894373;
RX   PubMed=30971826;
RX   PubMed=35839778;
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: COSMIC cell lines project.
CC   Population: Japanese.
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Cys135Phe (c.404G>T); ClinVar=VCV000376559; Zygosity=Homozygous (Cosmic-CLP).
CC   Omics: CRISPR phenotypic screen.
CC   Omics: Deep exome analysis.
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Genome ancestry: African=0%; Native American=1.29%; East Asian, North=74.96%; East Asian, South=23.74%; South Asian=0%; European, North=0%; European, South=0% (PubMed=30894373).
CC   Derived from site: Metastatic; Bone marrow; UBERON=UBERON_0002371.
ST   Source(s): Cosmic-CLP
ST   Amelogenin: X,Y
ST   CSF1PO: 10,11
ST   D13S317: 8,12
ST   D16S539: 10
ST   D5S818: 9,13
ST   D7S820: 10,12
ST   TH01: 7
ST   TPOX: 9,11
ST   vWA: 14
DI   NCIt; C4827; Adrenal gland neuroblastoma
DI   ORDO; Orphanet_635; Neuroblastoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   4Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 30-01-24; Version: 35
//
RX   CelloPub=CLPUB00582;
RA   Sugimoto T., Kuroda H., Yagyu S., Gotoh T., Osone S., Tamura S.,
RA   Iehara T., Hosoi H.;
RT   "Cellular and molecular characteristics of established neuroblastoma
RT   cell lines.";
RL   J. Cancer Res. Therap. Oncol. 7:201.1-201.15(2019).
//
RX   PubMed=10363161;
RA   Yagi M., Sugimoto T., Mine H., Horii Y., Matsumura T., Sawada T.,
RA   Abe T., Sano K., Goshi J., Takahashi K.;
RT   "Basic calponin expressing human neuroblastoma cell line of KP-N-YS.";
RL   Hum. Cell 11:231-238(1998).
//
RX   PubMed=11129446; DOI=10.1097/00019606-200012000-00007;
RA   Sugimoto T., Mine H., Horii Y., Takahashi K., Nagai R., Morishita R.,
RA   Komada M., Asada Y., Sawada T.;
RT   "Neuroblastoma cell lines showing smooth muscle cell phenotypes.";
RL   Diagn. Mol. Pathol. 9:221-228(2000).
//
RX   PubMed=12702577;
RA   Saito-Ohara F., Imoto I., Inoue J., Hosoi H., Nakagawara A.,
RA   Sugimoto T., Inazawa J.;
RT   "PPM1D is a potential target for 17q gain in neuroblastoma.";
RL   Cancer Res. 63:1876-1883(2003).
//
RX   PubMed=20164919; DOI=10.1038/nature08768;
RA   Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S.,
RA   Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S.,
RA   Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T.,
RA   Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.;
RT   "Signatures of mutation and selection in the cancer genome.";
RL   Nature 463:893-898(2010).
//
RX   PubMed=23268333; DOI=10.1016/j.canlet.2012.12.011;
RA   Sugimoto T., Gotoh T., Yagyu S., Kuroda H., Iehara T., Hosoi H.,
RA   Ohta S., Ohira M., Nakagawara A.;
RT   "A MYCN-amplified cell line derived from a long-term event-free
RT   survivor among our sixteen established neuroblastoma cell lines.";
RL   Cancer Lett. 331:115-121(2013).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S.,
RA   Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P.,
RA   Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H.,
RA   Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=30971826; DOI=10.1038/s41586-019-1103-9;
RA   Behan F.M., Iorio F., Picco G., Goncalves E., Beaver C.M.,
RA   Migliardi G., Santos R., Rao Y., Sassi F., Pinnelli M., Ansari R.,
RA   Harper S., Jackson D.A., McRae R., Pooley R., Wilkinson P.,
RA   van der Meer D.J., Dow D., Buser-Doepner C.A., Bertotti A., Trusolino L.,
RA   Stronach E.A., Saez-Rodriguez J., Yusa K., Garnett M.J.;
RT   "Prioritization of cancer therapeutic targets using CRISPR-Cas9
RT   screens.";
RL   Nature 568:511-516(2019).
//
RX   PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010;
RA   Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N.,
RA   Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J.,
RA   Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L.,
RA   Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S.,
RA   Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B.,
RA   Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.;
RT   "Pan-cancer proteomic map of 949 human cell lines.";
RL   Cancer Cell 40:835-849.e8(2022).
//